Cargando…

Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction

PURPOSE: To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e′, and E/e′) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tymińska, Agata, Kapłon-Cieślicka, Agnieszka, Ozierański, Krzysztof, Budnik, Monika, Wancerz, Anna, Sypień, Piotr, Peller, Michał, Balsam, Paweł, Opolski, Grzegorz, Filipiak, Krzysztof J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811795/
https://www.ncbi.nlm.nih.gov/pubmed/31687050
http://dx.doi.org/10.1155/2019/9529053
_version_ 1783462538973806592
author Tymińska, Agata
Kapłon-Cieślicka, Agnieszka
Ozierański, Krzysztof
Budnik, Monika
Wancerz, Anna
Sypień, Piotr
Peller, Michał
Balsam, Paweł
Opolski, Grzegorz
Filipiak, Krzysztof J.
author_facet Tymińska, Agata
Kapłon-Cieślicka, Agnieszka
Ozierański, Krzysztof
Budnik, Monika
Wancerz, Anna
Sypień, Piotr
Peller, Michał
Balsam, Paweł
Opolski, Grzegorz
Filipiak, Krzysztof J.
author_sort Tymińska, Agata
collection PubMed
description PURPOSE: To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e′, and E/e′) in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). METHODS: A prospective, observational study, BIOSTRAT (Biomarkers for Risk Stratification After STEMI), enrolled 117 patients between October 2014 and April 2017. Gal-3 and sST2 serum collection and echocardiography were performed twice (during index hospitalization and on a control visit at one-year follow-up). The primary endpoint was HF onset at one-year follow-up. Secondary assessments included associations of biomarker concentration with echocardiographic indices of systolic and diastolic dysfunction at baseline and at one year. RESULTS: Mean baseline concentrations of Gal-3 and sST2 (7.5 and 26.4 ng/mL, respectively) were significantly increased at one-year follow-up (8.5 ng/mL and p < 0.001 and 31.4 ng/mL and p = 0.001, respectively). Patients who reached the primary endpoint (50 patients (48%)) had significantly higher baseline concentrations of both biomarkers and a higher Gal-3 level at one year compared to patients who did not. Both Gal-3 and sST2 were predictors of the primary endpoint in univariate logistic regression analysis, but only Gal-3 remained significant in multivariate analysis. There was no clear association between both biomarkers and echocardiographic parameters. CONCLUSIONS: Baseline, but not one-year, changes of Gal-3 and sST2 concentrations may be useful for risk stratification after STEMI. However, only Gal-3 was the independent predictor of HF development at one-year observation. This trial is registered with NCT03735719.
format Online
Article
Text
id pubmed-6811795
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68117952019-11-04 Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction Tymińska, Agata Kapłon-Cieślicka, Agnieszka Ozierański, Krzysztof Budnik, Monika Wancerz, Anna Sypień, Piotr Peller, Michał Balsam, Paweł Opolski, Grzegorz Filipiak, Krzysztof J. Dis Markers Research Article PURPOSE: To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e′, and E/e′) in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). METHODS: A prospective, observational study, BIOSTRAT (Biomarkers for Risk Stratification After STEMI), enrolled 117 patients between October 2014 and April 2017. Gal-3 and sST2 serum collection and echocardiography were performed twice (during index hospitalization and on a control visit at one-year follow-up). The primary endpoint was HF onset at one-year follow-up. Secondary assessments included associations of biomarker concentration with echocardiographic indices of systolic and diastolic dysfunction at baseline and at one year. RESULTS: Mean baseline concentrations of Gal-3 and sST2 (7.5 and 26.4 ng/mL, respectively) were significantly increased at one-year follow-up (8.5 ng/mL and p < 0.001 and 31.4 ng/mL and p = 0.001, respectively). Patients who reached the primary endpoint (50 patients (48%)) had significantly higher baseline concentrations of both biomarkers and a higher Gal-3 level at one year compared to patients who did not. Both Gal-3 and sST2 were predictors of the primary endpoint in univariate logistic regression analysis, but only Gal-3 remained significant in multivariate analysis. There was no clear association between both biomarkers and echocardiographic parameters. CONCLUSIONS: Baseline, but not one-year, changes of Gal-3 and sST2 concentrations may be useful for risk stratification after STEMI. However, only Gal-3 was the independent predictor of HF development at one-year observation. This trial is registered with NCT03735719. Hindawi 2019-10-10 /pmc/articles/PMC6811795/ /pubmed/31687050 http://dx.doi.org/10.1155/2019/9529053 Text en Copyright © 2019 Agata Tymińska et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tymińska, Agata
Kapłon-Cieślicka, Agnieszka
Ozierański, Krzysztof
Budnik, Monika
Wancerz, Anna
Sypień, Piotr
Peller, Michał
Balsam, Paweł
Opolski, Grzegorz
Filipiak, Krzysztof J.
Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
title Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
title_full Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
title_fullStr Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
title_full_unstemmed Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
title_short Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
title_sort association of galectin-3 and soluble st2, and their changes, with echocardiographic parameters and development of heart failure after st-segment elevation myocardial infarction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811795/
https://www.ncbi.nlm.nih.gov/pubmed/31687050
http://dx.doi.org/10.1155/2019/9529053
work_keys_str_mv AT tyminskaagata associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT kapłoncieslickaagnieszka associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT ozieranskikrzysztof associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT budnikmonika associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT wancerzanna associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT sypienpiotr associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT pellermichał associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT balsampaweł associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT opolskigrzegorz associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction
AT filipiakkrzysztofj associationofgalectin3andsolublest2andtheirchangeswithechocardiographicparametersanddevelopmentofheartfailureafterstsegmentelevationmyocardialinfarction